Course: Aspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women
CME Credits: 1.00
Released: 2022-07-25
The efficacy of aspirin for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has been well established in both men and women; however, evidence on aspirin use for primary prevention has been controversial. In 2022, the US Preventive Services Task Force (USPSTF) released new recommendations that advise against the use of aspirin for primary prevention of ASCVD in adults 60 years or older (grade D; recommend against initiating), with no differences in treatment effect or guidance by sex. For primary prevention in individuals aged 40 to 59 years who have an estimated 10-year ASCVD risk of at least 10% per the American College of Cardiology/American Heart Association pooled cohort equations, a grade C recommendation was given, indicating that there is at least moderate certainty that the net benefit in this group is small and shared decision-making should be considered on a case-by-case basis.
To identify the key insights or developments described in this article
View Full Course